Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent ...

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.Results suggest that nuclear GSK-3β ...
Rasplin on MSN

When your teammate doesn’t listen

In this Minecraft video, I warn another player about what’s coming, but he completely ignores it, leading to a funny in-game moment. The session follows how the situation starts, what goes wrong, and ...
The Manila Times

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy i…

The combination was well tolerated: no treatment-related deaths occurred, and only 6% (2 patients) were discontinued due to ...
Barron's

Kinross Gold Corp.

Complete Kinross Gold Corp. stock information by Barron's. View real-time K stock price and news, along with industry-best analysis.